Member Info for technick

Missed trade sale :-p

Agree scart. The CE IVD approvals process is still a self documented process, straightforward to do and I suspect that will come first, then a distribution deal would wrap it up nicely.

I guess somewhat related to the market cap discussion is it more the value traded rather than the number of shares that’s important. I suspect with the rising share price less shares are traded but the same value, or is it number of shares and the percentage of issued shares traded that’s important. I can argue it both ways!

Any rise is good, should continue tomorrow and some RNSs on deals shortly.

What are people’s views on valuation if we hit similar £90m orders for C19 as NCYT. The world is crying out of tests and no single player can fill the demand. If we are hitting those figures then MC should be in the 5x multiples assuming tests required for the next few years? Any views from anyone?

... I still think we can push to £1.50 today in the run up until close....

Agree with Alwaysone, perhaps there's even a more strategic tie up that makes it a US product for example, US owned business

thank you Milcait

Milcait please can you say where that came from?

Testing is going to be with us for a while yet until an effective vaccine is in place, moat likely next year. If the virus is like a cold (another coronavirus by the way) then there won't be an effective vaccine because it will keep changing an invading immunity. Testing could be with us for a long time to come. Opinion.

I wonder what will come next for us, I'm hoping for a nice sales and distribution agreement from Cytiva, dare we dream for more?

10k tests an hour! In the UK alone, what it is globally I have no idea!

Probably covered but this from Novacyt's RNA this morning 'As of 28 April 2020, Primerdesign has sold, received orders for or has been contracted to deliver over £90 million (€103 million) of its COVID-19 test.' Wow, and the market is much bigger than that and we have a more volume orientated product that can be shipped world wide! If we have a similar scale then what should our market cap be?

I agree Scart, I think the board seem wise to the opportunities for non-diluting equity

I agree with regards to liquidity, there are a lot of holders sat on 5x and 10x gains which means placing these into market is more difficult with a rising share price... maybe the company could also do a 1 to 10x or something similar...

... current market cap would be a supported by a £10m turnover with a 5x multiple. We see this potential with just one of the 3 assays already just coming on to market so there is an argument that C19 isn't yet reflected in the share price... what do others think?

at £5-£10 per test, that's a turnover of up to £16m every 20 days!

my prediction yesterday was almost bang on, let's see if todays 150p prediction is where we end up, my prediction on market cap once we register first qtr sales is £200m

My guess is another 25% tomorrow, higher if there’s an rns first thing

£5 gives a market cap of £175m. Based on a U.K. market of £1bn that is likely to require multiple suppliers, and given the U.K. is 3% of the global market I do think this is highly achievable. I think NVCT and GDR will become the molecular qPCR groups in the U.K. And go on to service other countries to. If that happens £5 very possible short term.